Approximately 800,000 individuals in Türkiye are battling dementia illnesses, with Alzheimer‘s being one of the vital vital amongst them.
The newly developed drug known as “Donanemab” has raised hope for sufferers and their households.
Research on the drug was printed within the globally famend scientific medical journal “The Journal Of The American Medical.”
According to the examine carried out amongst 1,736 people aged between 60 and 85, the brand new Alzheimer’s drug slows down the development of the illness’s signs by 30%.
“PROGRESSION OF THE DISEASE SLOWED BY 30-40% AFTER 18 MONTHS”
Prof. Dr. Haşmet Hanağası, Head of the Department of Neurology at Istanbul University Faculty of Medicine, acknowledged that the drug represents a major development in Alzheimer’s illness remedy and mentioned:
“This is a drug aimed at slowing down the progression of Alzheimer’s disease, and it has been observed that after an 18-month period of use, patients experienced a slowdown in disease progression by approximately 30 to 40% compared to those who didn’t use it. This is undoubtedly a major development for Alzheimer’s disease, as these are the first drugs that have a positive impact on the course of the disease.”
TO BE RELEASED NEXT YEAR
The drug was developed to clear the sticky substance known as “Beta Amyloid” shaped within the brains of Alzheimer’s sufferers. It is used within the early levels of the illness.
Hanağası emphasised that the medication are efficient in early diagnoses.
The drug is anticipated to be launched in the marketplace subsequent 12 months.
Source: www.anews.com.tr
